Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma

Introduction: The presence of HER-2 has been shown to be a prognostic factor in many kinds of cancers, but its role in head and neck squamous cell carcinoma (HNSCC) is not still defined. The purpose of the current study is to investigate the role of HER-2 in HNSCC and its correlation with various clinicopathologic parameters. Materials and Methods: Peripheral blood samples were obtained from 17 healthy volunteers and 69 patients with HNSCC before curative surgery. The HER-2 level was determined in each sample sandwich by ELISA. Statistical analysis was performed using an independent t-test, one-way ANOVA, and the Duncan procedure. Results: Mean HER-2 serum levels were higher in patients with HNSCC compared with healthy controls, although the difference was not statistically significant (3.85ng/ml vs. 3.75ng/ml; P>0.05). The mean serum level of HER-2 in patients with was higher in patients with lymph node involvement, metastasis, invasion, tumor size ≥2 cm, and stage>1, although the differences were not statistically significant (P>0.05). Discussion: Mean HER-2 serum levels in patients with tumor size T3 and higher were higher than those from patients in stage T1 and T2.over expression of these receptor translate into disease progression, growth and invasiveness, with the increase serum HER-2 levels in such patients offering some support for this theory. Conclusion: In this study the mean HER-2 serum level in patients with HNSCC was found to be greater in comparison with the healthy control group, although the difference was statistically insignificant. From the analysis of the results of the current study we have come to the conclusion that by increasing sample size the rising of the serum HER-2 level in patients with HNSCC can be meaningful. Apart from this, the role of HER-2 as a tumor marker in patients with HNSCC is still controversial and needs further studies to clarify the significance of this biomarker for early detection or screening for HNSCC.

[1]  C. Moskaluk,et al.  Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma , 2011, Journal of Translational Medicine.

[2]  F. Dias,et al.  Expression of Bcl-2 family proteins and associated clinicopathologic factors predict survival outcome in patients with oral squamous cell carcinoma. , 2009, Oral oncology.

[3]  T. McDonnell,et al.  The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death , 2009, Apoptosis.

[4]  I. Cha,et al.  Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. , 2008, Human pathology.

[5]  B. Park,et al.  p21 and p27: roles in carcinogenesis and drug resistance , 2008, Expert Reviews in Molecular Medicine.

[6]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[7]  H. Nordgren,et al.  EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases , 2008, Annals of Surgical Oncology.

[8]  T. Martone,et al.  Prognostic impact of HER‐2/neu expression on squamous head and neck carcinomas , 2007, Head & neck.

[9]  C. Hwang,et al.  High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis , 2006, Journal of surgical oncology.

[10]  C. Su,et al.  High Expression of CD105 as a Prognostic Predictor of Early Tongue Cancer , 2006, The Laryngoscope.

[11]  B. Bouchet,et al.  p53 as a target for anti-cancer drug development. , 2006, Critical reviews in oncology/hematology.

[12]  Johannes Gerdes,et al.  Ki‐67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells , 2006, Journal of cellular physiology.

[13]  C. Lindsley,et al.  The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. , 2005, Current topics in medicinal chemistry.

[14]  Shilpi Arora,et al.  Stromelysin 3, Ets-1, and Vascular Endothelial Growth Factor Expression in Oral Precancerous and Cancerous Lesions: Correlation with Microvessel Density, Progression, and Prognosis , 2005, Clinical Cancer Research.

[15]  M. Fresno,et al.  Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. , 2005, Oral oncology.

[16]  Manuel Hidalgo,et al.  Developing inhibitors of the epidermal growth factor receptor for cancer treatment. , 2003, Journal of the National Cancer Institute.

[17]  K. Kono,et al.  Status of c‐erbB‐2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme‐linked immuno‐sorbent assay , 2002, International journal of cancer.

[18]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Kitano,et al.  Immunohistochemical Study of c-erbB-2 Protein in Colorectal Cancer and the Correlation with Patient Survival , 1998, Oncology.

[20]  L. Pavelic,et al.  Expression of c-erbB-2 gene in human head and neck carcinoma. , 1992, Anticancer research.

[21]  D. Spandidos,et al.  C-erbB-2 expression in squamous cell carcinoma of the head and neck. , 1992, Anticancer research.

[22]  I. Summerhayes,et al.  Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. , 1989, Oncogene.

[23]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[24]  M. Gapany.  Biological Markers and Prognosis in Recurrent Oral Cancer After Salvage Surgery , 2009 .

[25]  S. Robbins,et al.  The Eph receptor/ephrin system: an emerging player in the invasion game. , 2008, Current issues in molecular biology.

[26]  M. Arcasoy,et al.  Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  M. Wagenmann,et al.  Serum level and tissue expression of c-erbB-1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck. , 2001, Oral oncology.